Toward organometallic antischistosomal drug candidates

Future Med Chem. 2015;7(6):821-30. doi: 10.4155/fmc.15.22.

Abstract

In the recent years, there has been a growing interest in the use of novel approaches for the treatment of parasitic diseases such as schistosomiasis. Among the different approaches used, organometallic compounds were found to offer unique opportunities in the design of antiparasitic drug candidates. A ferrocenyl derivative, namely ferroquine, has even entered clinical trials as a novel antimalarial. In this short review, we report on the studies describing the use of organometallic compounds against schistosomiasis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antifungal Agents / chemistry
  • Antifungal Agents / pharmacology
  • Antimalarials / chemistry
  • Antimalarials / pharmacology
  • Drug Discovery
  • Drug Repositioning
  • Humans
  • Organometallic Compounds / chemistry*
  • Organometallic Compounds / pharmacology*
  • Praziquantel / analogs & derivatives
  • Praziquantel / pharmacology
  • Schistosoma / drug effects*
  • Schistosomiasis / drug therapy*
  • Schistosomiasis / parasitology
  • Schistosomicides / chemistry*
  • Schistosomicides / pharmacology*

Substances

  • Antifungal Agents
  • Antimalarials
  • Organometallic Compounds
  • Schistosomicides
  • Praziquantel